Stocktoria

Barinthus Biotherapeutics plc. BRNS

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-04-30 · LEI

Barinthus Biotherapeutics plc. statistics & valuation

Market cap$29.4M
P / B0.4×
Return on equity-89.4%
Return on capital-80%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202020212022202320242025
Operating margin (%)
-415.80% -16873.50% -9.00% -10463.10% -454.10% 202020212022202320242025
Return on equity (%)
-20.10% 2.20% -39.20% -46.90% -89.40% 202020212022202320242025
Shares outstanding
8.0M 37.2M 38.2M 38.6M 40.2M 40.8M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-34.90% -18.10% 2.00% -34.20% -38.10% -67.70% 202020212022202320242025
Free cash flow margin (%)
-234.80% -12585.40% -46.00% -7024.70% -199.30% 202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
-$2.24 -$1.96 $0.14 -$1.91 -$1.55 -$1.64 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin—-454.1%-10463.1%-9.0%-16873.5%-415.8%
Net margin—-408.0%-9145.5%11.9%-18979.5%-367.3%
FCF margin—-199.3%-7024.7%-46.0%-12585.4%-234.8%
Return on assets-67.7%-38.1%-34.2%2.0%-18.1%-34.9%
Return on equity-89.4%-46.9%-39.2%2.2%-20.1%48.0%
Current ratio7.778.0312.4517.4020.326.27

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.